Skip to main content

Table 5 LSM before and 72 weeks after SMV/SOF therapy in SVR patients

From: NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy

Baseline liverfibrosis stage Mean liver stiffnessbefore treatment(baseline) (kPa),mean ± SD Mean liver stiffness72 weeks aftertreatment (kPa),mean ± SD P value
F1 (n = 4) 6.4 ± 0.5 5.4 ± 0.9 0.088 ns
F2 (n = 17) 8.5 ± 0.5 6.1 ± 1.3 0.001*
F3 (n = 10) 10.7 ± 0.7 6.9 ± 2 0.001*
F4 (n = 16) 24.9 ± 6.9 20.7 ± 5.6 < 0.05*
Total (n = 47) 15.12 ± 0.54 10.27 ± 0.97 0.001*
  1. *Statistically significant